---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-015054"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2025-09-26T23:59:59+00:00"
generated_at: "2026-05-17T05:32:52.982789+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harrow signs definitive deal to acquire Melt Pharma for initial $4.3M plus milestones up to ~$352.5M

## Summary
- Initial cash payment of ~$4.3M for remaining 55% equity; contingent $87.2M upon FDA approval of MELT-300.
- Upon CMS J-Code assignment, Harrow will issue ~1.112M shares of common stock.
- Additional cash payments up to ~$261M based on annual net sales milestones ($100M–$1B).
- Harrow plans NDA submission in 2027, potential US launch in 2028 for MELT-300 sublingual sedation.
- Deal approved by independent committee; fairness opinion from Lake Street Capital Markets.

## SEC filing metadata
- accession: 0001493152-25-015054
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2025-09-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315225015054/0001493152-25-015054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315225015054/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-015054
- JSON: https://secwatch.observer/filing/0001493152-25-015054.json
- Plain text: https://secwatch.observer/filing/0001493152-25-015054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.